AFM
LTRN icon

Anson Funds Management’s Lantern Pharma LTRN Stock Holding History

Anson Funds Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-64,999
Closed -$519K – 398
2021
Q4 		$519K Buy
+64,999
New +$594K 0.05% 225

Other funds holding LTRN

SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Anson Funds Management's LTRN Position: Q1 2022 in Review

Anson Funds Management sold out of Lantern Pharma (LTRN) in Q1 2022, closing a stake of 64,999 shares — an estimated $519K sold.

Anson Funds Management first reported a position in LTRN in Q4 2021 and held it in 1 quarter. The position peaked at $519K in Q4 2021. 25 funds tracked by Wall St. Rank hold LTRN as of Q1 2022.

  • Anson Funds Management reported no remaining Lantern Pharma position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 64,999 Lantern Pharma shares in Q1 2022, an estimated $519K.
  • Anson Funds Management first reported a position in Lantern Pharma in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Lantern Pharma position peaked at $519K in Q4 2021.
  • 25 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.